said in the press note that it has received two observations from the US health regulator for its Telangana facility.
The US Food and Drug Administration (USFDA) inspected the company's finished dosage formulation facility located at Pharmaceutical Formulations SEZ, APIIC, Jadcherla (Telangana state) from August 29 to September 6, 2019, the company said in a filing on September 7.
There were no repeat observations or Data Integrity (DI) related observations. The company is the confidence of addressing these observations and responding to the USFDA at the earliest, the company added.
On Friday, Shilpa Medicare Ltd shares ended at Rs258.60, up by Rs13.95 or 5.7% from its previous closing of Rs244.65 on the BSE.
The scrip opened at Rs225.15 and touched a high and low of Rs260.70 and Rs225.15 respectively.